ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 293

False Positives in the Ultrasound Diagnosis of Giant Cell Arteritis: Some Diseases Can Also Have Halo Sign

Elisa Fernández1, Irene Monjo 2, Gema Bonilla 3, Chamaida Plasencia 4, Maria-Eugenia Miranda-Carus 2, Alejandro Balsa 4 and Eugenio de Miguel 5, 1Rheumatology Department, La Paz University Hospital, Madrid, Madrid, Spain, 2FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, Spain, 3Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, Madrid, Spain, 4Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, 5Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain

Meeting: ACR/ARP Annual Meeting 2019

Keywords: Doppler ultrasound, giant cell arteritis, large vessel vasculitis, temporal arteritis and systemic vasculitides

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Imaging Of Rheumatic Diseases Poster I

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis in the elderly. The halo sign is an accepted valid test for the diagnosis of GCA in trained units. However, other conditions can also produce a hypoechoic increase of the arterial wall thickness and mimic the halo sign. Our aim was to describe the frequency and causes of false positives in the diagnosis of GCA by color Doppler ultrasound (CDUS).

Methods: We performed an observational retrospective study of 305 patients with temporal artery CDUS findings compatible with GCA. Their medical records were reviewed to collect demographic, physical examination, clinical and analytical data. The medical diagnosis based on the clinical evolution of the patient during at least 1 year of follow-up was established as the gold standard for definitive diagnosis.

Results: 14 of the 305 included cases (4.6%) were false positives. The characteristics of these 14 patients and their final diagnoses are shown in table 1. 64% were female. The median age was 72 (interquartile range 68-79) years. The median erythrocyte sedimentation rate was 55 (32-110) mm/h, C-reactive protein 15.1 (7.3-100.9) mg/L and hemoglobin 13.3 (11.2-14.1) g/dL. Five patients (36%) fulfilled the 1990 American College of Rheumatology classification criteria. A temporal artery biopsy was performed in 9 patients (64%), with negative results in all of them. Twelve patients (86%) had CDUS involvement of the superficial temporal arteries. Five had 1 branch involved (42%), three 2 branches (25%), two 3 branches (17%) and two 4 branches (17%). In addition, two patients (14%) had an isolated halo sign in the axillary arteries, one unilateral and the other bilateral. Regarding the definitive diagnosis, in four patients it was polymyalgia rheumatica (29%), in three atherosclerosis (21%), and there was one case each of non-Hodgkin’s Lymphoma type T, osteomyelitis of the skull base, primary amyloidosis associated with multiple myeloma, granulomatosis with polyangiitis, neurosyphilis, urinary sepsis and narrow-angle glaucoma.

Conclusion: CDUS diagnosis of GCA yields a low percentage of false positives. These are attributable either to operator-dependent technical mistakes or to the presence of other medical conditions that alter the US signal of the arterial wall, resulting in a halo sign. The clinician must be aware of the existence of these conditions when interpreting this test, in order to improve the diagnostic accuracy of the CDUS.


Table 1


Disclosure: E. Fernández, None; I. Monjo, BMS, 2; G. Bonilla, None; C. Plasencia, None; M. Miranda-Carus, BMS, 2, Roche Pharma, 2; A. Balsa, BMS, 2, Roche Pharma, 2; E. de Miguel, AbbVie, 2, 5, 8, BMS, 8, BMS, MSD, UCB, Roche, 8, MSD, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Roche, 8, UCB, 8.

To cite this abstract in AMA style:

Fernández E, Monjo I, Bonilla G, Plasencia C, Miranda-Carus M, Balsa A, de Miguel E. False Positives in the Ultrasound Diagnosis of Giant Cell Arteritis: Some Diseases Can Also Have Halo Sign [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/false-positives-in-the-ultrasound-diagnosis-of-giant-cell-arteritis-some-diseases-can-also-have-halo-sign/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARP Annual Meeting 2019

ACR Meeting Abstracts - https://acrabstracts.org/abstract/false-positives-in-the-ultrasound-diagnosis-of-giant-cell-arteritis-some-diseases-can-also-have-halo-sign/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology